Men more than three times as likely to die from a brain injury, study shows
A new analysis of U.S. mortality data reveals the disproportionate impact of traumatic brain injuries (TBI) on older adults, males and certain racial and ethnic groups.
MyBlueDots
Category Added in a WPeMatico Campaign
Read More
Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
TOKYO–(BUSINESS WIRE)–LAVATECH, which has a high far-infrared effect, to be unveiled for the first time at an international trade fair for home and contract textiles.
Meiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy
TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network.
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Amylyx. In addition, Amylyx intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the public offering at the public offering price per share, less underwriting
Thermo Fisher Scientific’s Olink Platform Selected for World’s Largest Human Proteome Study
WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world’s largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. Through this collaboration, Zai Lab further expands its global oncology pipeline with anoth
AHF to Meta: Sexual Orientation is not Mental Illness
LOS ANGELES–(BUSINESS WIRE)–AHF to Meta: Sexual Orientation is not Mental Illness
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025. The fireside chat
Researchers identify risk factors for poor prognosis in alopecia areata
Alopecia areata (AA) is a common autoimmune disease that leads to sudden circular hair loss. The clinical course of AA is unpredictable and varies greatly from individual to individual. Numerous studies have shown that AA is often associated with comorbid, i.e. co-existing, chronic inflammatory diseases, which can have an impact on prognosis and clinical management.
The basis of voluntary movements: Monkey study challenges classical views on how brain controls natural actions
A study published in Science reveals new mechanisms through which the brain controls natural actions. The results challenge some of the classical views about how the motor system works and open up possible new applications in neurorehabilitation and robotics.